Teva Pharmaceutical ( Teva Pharmaceutical )

Teva Pharmaceutical

Teva Pharmaceutical's picture

About Teva Pharmaceutical

The foundation of our success, and at the heart of Teva, is our vision to be the most indispensable medicines company for the world, executing on our obligation to our patients, customers, shareholders and employees.

Established in 1901, today we rank among the 10 top pharmaceutical companies in the world. Headquartered in Israel, Teva is active in 60 countries, with over 46,400 dedicated employees worldwide.

Teva Pharmaceutical press release, blog etc

10/20/2018 - 22:01 Teva and New Jersey Governor Murphy Formalize North America Headquarters Move with Ceremony in Israel
10/11/2018 - 15:24 Teva Draws on Patient Experience to Empower Those Living with Chronic Conditions
10/10/2018 - 16:07 Celltrion and Teva Announce FDA Oncologic Drugs Advisory Committee Recommends Approval of Celltrion BLA for CT-P10, a Proposed Rituximab Biosimilar
10/10/2018 - 15:52 Teva Presents 25-year Safety Data from Longest Continuous Trial of COPAXONE (glatiramer acetate injection) for the Treatment of Relapsing Forms of Multiple Sclerosis
10/07/2018 - 19:47 Teva to Present New Data at 34th European Committee for Treatment and Research in Multiple Sclerosis Congress in Berlin
09/27/2018 - 06:09 Teva Announces Exclusive First-to-File Launch of a Generic Version of Cialis in the United States
09/18/2018 - 02:22 Teva Announces Early Results of Debt Tender Offer and Election of Early Settlement
09/13/2018 - 19:15 Teva Announces U.S. Approval of AJOVY (TM) (fremanezumab-vfrm) Injection
09/13/2018 - 18:55 Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults
09/11/2018 - 19:52 Teva to Present at the Morgan Stanley Global Healthcare Conference
09/03/2018 - 22:55 Teva Announces $400 Million Debt Tender Offer
08/16/2018 - 02:55 Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
08/06/2018 - 05:34 Teva Announces Updated Indication and Vial Presentation for GRANIX (tbo-filgrastim) Injection in United States
07/17/2018 - 19:16 Teva Highlights Key Milestones Achieved in the 2017 Social Impact Report
07/09/2018 - 05:41 Teva Announces Launch of a Generic Version of Uceris in the United States
06/28/2018 - 18:16 Teva to Present New Fremanezumab Data, Including Long-Term Data, at the American Headache Societys 60th Annual Scientific Meeting
06/15/2018 - 08:49 Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache
05/23/2018 - 03:21 Teva Confirms September PDUFA Date for Fremanezumab